"In this report, we look at one of the crucial pieces of the jigsaw – healthcare innovation. As one of the
largest components of age-related public spending, healthcare is at the forefront of the challenge of
ageing. While ensuring that we have a good healthcare system that requires continual improvements in
the quality of services for users, it also requires improvements in the efficiency of the system to ensure its
long run survival."
Towards affordable
healthcare: Why effective
innovation is key
SM Bamford, B Franklin, D Hochlaf, G Holley-Moore
International Longevity Centre - UK
June 2017
Read more here.
QIPP stands for Quality, Innovation, Productivity and Prevention. The aim of this initiative is to help health care organisations deliver higher quality care and operate more efficiently and effectively.
Showing posts with label affordability. Show all posts
Showing posts with label affordability. Show all posts
Thursday, 27 July 2017
Monday, 23 March 2015
Debt financing of breakthrough treatments
"Debt-financing schemes for breakthrough pharmaceutical products might offer a win-win-win for patients, payers, and manufacturers. Patients would obtain access to medicines; payers could ensure such access while remaining fiscally prudent. For pharmaceutical companies, entering into such a scheme would clearly be a better business and public relations strategy than fighting discounts and coverage denials."
Borrowing for the cure: Debt financing of breakthrough treatments
S Mattke, E Hoch
RAND Corporation
March 2015
Read more here.
Borrowing for the cure: Debt financing of breakthrough treatments
S Mattke, E Hoch
RAND Corporation
March 2015
Read more here.
Labels:
affordability,
breakthrough treatments,
cost-effectiveness,
debt financing,
high-cost drugs,
innovation,
specialty drugs
Subscribe to:
Posts (Atom)